Advertisement

Topics

Johnson & Johnson Acquire BeneVir Biopharm

09:38 EDT 2 May 2018 | Pharmaceutical Processing

Janssen will gain Benevir Biopharm's oncolytic immunotherapy platform in the acquisition.
Contributed Author: 
HC2 Holdings, Inc.
Topics: 

Original Article: Johnson & Johnson Acquire BeneVir Biopharm

NEXT ARTICLE

More From BioPortfolio on "Johnson & Johnson Acquire BeneVir Biopharm"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...